GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NervGen Pharma Corp (STU:9UA) » Definitions » YoY Rev. per Sh. Growth

NervGen Pharma (STU:9UA) YoY Rev. per Sh. Growth : 0.00% (As of Mar. 2025)


View and export this data going back to 2024. Start your Free Trial

What is NervGen Pharma YoY Rev. per Sh. Growth?

YoY Rev. per Sh. Growth is the percentage change of Revenue per Share over the past twelve months. NervGen Pharma's YoY Rev. per Sh. Growth for the quarter that ended in Mar. 2025 was 0.00%.

NervGen Pharma's Revenue per Share for the three months ended in Mar. 2025 was €0.00.

NervGen Pharma YoY Rev. per Sh. Growth Historical Data

The historical data trend for NervGen Pharma's YoY Rev. per Sh. Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NervGen Pharma YoY Rev. per Sh. Growth Chart

NervGen Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
YoY Rev. per Sh. Growth
Get a 7-Day Free Trial - - - - -

NervGen Pharma Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
YoY Rev. per Sh. Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

NervGen Pharma YoY Rev. per Sh. Growth Calculation

YoY Rev. per Sh. Growth is the percentage change of Revenue per Share over the past twelve months.

NervGen Pharma's YoY Rev. per Sh. Growth for the fiscal year that ended in Dec. 2024 is calculated as:

YoY Rev. per Sh. Growth (A: Dec. 2024 )
=(Revenue per Share (A: Dec. 2024 )-Revenue per Share (A: Dec. 2023 ))/ | Revenue per Share (A: Dec. 2023 ) |
=(0-0)/ | 0 |
=N/A %

NervGen Pharma's YoY Rev. per Sh. Growth for the quarter that ended in Mar. 2025 is calculated as:

YoY Rev. per Sh. Growth (Q: Mar. 2025 )
=(Revenue per Share (Q: Mar. 2025 )-Revenue per Share (Q: Mar. 2024 )) / | Revenue per Share (Q: Mar. 2024 )) |
=(0-0)/ | 0 |
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NervGen Pharma YoY Rev. per Sh. Growth Related Terms

Thank you for viewing the detailed overview of NervGen Pharma's YoY Rev. per Sh. Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

NervGen Pharma Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NervGen Pharma Corp (STU:9UA) » Definitions » YoY Rev. per Sh. Growth
Comparable Companies
TSX:FRX XCNQ:DRUG XCNQ:METX NEOE:CYBN TSX:EPRX TSX:TH TSX:MSCL TSXV:ARCH TSX:MDNA XCNQ:GLAB VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
NGENF:USA NGEN:Canada
Address
112-970 Burrard Street, Unit 1290, Vancouver, BC, CAN, V6Z 2R4
Website
https://www.nervgen.com
NervGen Pharma Corp is a clinical-stage biotech company. The company's principal business activity is the discovery, development, and commercialization of pharmaceutical treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. The company's initial target indication is spinal cord injury. The company's pipeline products include NVG-291 and NVG-300.

NervGen Pharma Headlines

No Headlines